Enzo Biochem Inc (N:ENZ)

Business Focus: Biotechnology & Medical Research

Mar 13, 2024 04:26 pm ET
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024. Second Quarter Highlights The Company's Life Science division's second-quarter revenue of $8.5...
Feb 01, 2024 08:30 am ET
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading life science company, announced the voting results from its Annual Meeting held on January 31, 2024 and officer appointments. Summary of the Fiscal Year 2023 Annual...
Dec 15, 2023 04:20 pm ET
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the first quarter ended October 31, 2023. First Quarter Highlights The Company's Life Sciences division's first quarter revenue...
Nov 06, 2023 08:00 am ET
ENZO BIOCHEM REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 RESULTS AND PROVIDES BUSINESS UPDATE
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update. Fourth Quarter...
Oct 30, 2023 04:15 pm ET
Steven J. Pully Appointed to Enzo Biochem’s Board of Directors
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading life sciences company, announced today that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of...
Sep 06, 2023 08:30 am ET
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
Enzo Biochem, Inc. (NYSE: ENZ) announced today that Hamid Erfanian, Chief Executive Officer (CEO), will be resigning his seat on the Board of Directors and departing the Company effective September 5, 2023, with Enzo’s Chief Operating Officer,...
Jul 24, 2023 04:27 pm ET
Enzo Biochem Completes Sale of Clinical Laboratory to Labcorp
Enzo Biochem, Inc. (NYSE:ENZ) today announced that it has closed a transaction to sell certain assets of Enzo’s Clinical laboratory division (Enzo Clinical Labs) to Laboratory Corporation of America Holdings (Labcorp) (NYSE:LH) pursuant to an Asset...
Jun 14, 2023 07:21 pm ET
Enzo Biochem Reports Third Quarter Fiscal Year 2023 Financial Results
Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, today filed its Form 10-Q for the third quarter ended April 30, 2023 of Fiscal Year 2023 (Q3 FY23). Enzo Biochem will not be hosting a financial webcast or call for...
Jun 02, 2023 01:15 pm ET
Federman & Sherwood Investigates Enzo Biochem for Data Breach
The law firm of Federman & Sherwood has initiated an investigation into Enzo Biochem with respect to their recent data breach. On May 30, 2023, Enzo Biochem notified 2.47 million patients that the company experienced a data breach after an unauthorized party accessed sensitive consumer data entrusted to the company. According to Enzo Biochem, they determined that information stored on their servers may have been subject to unauthorized access on April 6, 2023. Enzo Biochem determined that the information exposed in the data breach includes: names, addresses, Social Security numbers, driver’s l
May 22, 2023 09:20 am ET
Enzo Biochem Reports Significant Progress towards Completing the Clinical Lab Asset Sale
Enzo Biochem, Inc. (NYSE:ENZ), announced today that  the preliminary voting results from the Inspector of Election at today’s Special Meeting of the Shareholders indicate that the Asset Sale Proposal was approved by the affirmative vote of a...
May 17, 2023 05:26 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – CHRA, MYBF, MDWT, ENZ
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
May 10, 2023 05:44 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – MDWT, ENZ, CHRA, MYBF
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
May 04, 2023 04:10 pm ET
SHAREHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – RUTH, MDWT, ENZ, ARNC
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
May 02, 2023 08:30 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Enzo Biochem, Inc.
NEW YORK, May 2, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Enzo Biochem, Inc. ("Enzo Biochem" or the "Company") (NYSE: ENZ) in connection with its acquisition by Laboratory Corporation of America Holdings (NYSE: LH) ("Labcorp").  The transaction value is approximately $146 million.
Apr 24, 2023 04:05 pm ET
Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo Biochem” or the “Company”), a leading biosciences and diagnostics company, today announced that its special meeting of shareholders (the “Special Meeting”) to consider and vote on a proposal to approve the...
Mar 21, 2023 09:43 am ET
Enzo Biochem Reports Second Quarter Fiscal Year 2023 Financial Results
Enzo Biochem, Inc. (NYSE:ENZ), a pioneering biosciences and diagnostics company, filed its Form 10-Q for the second quarter ended January 31, 2023 of Fiscal Year 2023 (Q2 FY23). Enzo Biochem will not be hosting a financial webcast or call for this...
Mar 16, 2023 04:30 pm ET
Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp
Enzo Biochem, Inc. (NYSE:ENZ) announced today that it has entered into an agreement for Labcorp (NYSE: LH) to acquire the assets of Enzo’s Clinical Laboratory division (Enzo Clinical Labs). The transaction between two leading global life sciences...
Dec 12, 2022 05:29 pm ET
Enzo Biochem Reports First Quarter Fiscal Year 2023 Financial Results and Provides Business Update
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the first quarter ended October 31, 2022 of Fiscal Year 2023 (Q1 FY23) and provided a business update on recent corporate and...
Dec 07, 2022 06:18 pm ET
Enzo Biochem, Inc. to Report First Quarter Fiscal 2023 Financial Results and Business Update on Monday, December 12th
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter fiscal 2023 financial and operating results after the market close on Monday, December 12, 2022. The Form 10-Q filing...
Nov 08, 2022 06:04 pm ET
Enzo Biochem, Inc. Announces Date of Annual Shareholders’ Meeting
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that its Annual Shareholders’ Meeting will be held on January 31, 2023.  Shareholders must submit proposals and/or director...
Oct 31, 2022 08:30 am ET
Farmer Bros. Co. Announces Board Refresh and Cooperation Agreement with Stockholders JCP Investment Management and 22NW
Farmer Bros. Co. (NASDAQ: FARM) (the “Company”), today announced it has entered into a cooperation agreement (the “Cooperation Agreement”) with JCP Investment Management, LLC (collectively with its affiliates, “JCP”) and 22NW, LP (collectively with...
Oct 20, 2022 08:15 am ET
Enzo Biochem, Inc. Appoints Patricia Eckert, CPA as Interim CFO
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointment of Patricia Eckert, CPA, as interim Chief Financial Officer (CFO).  Ms. Eckert’s appointment follows the...
Oct 14, 2022 07:30 am ET
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the fiscal year and fourth quarter ended July 31, 2022 and provided a business update on recent corporate and operational...
Oct 10, 2022 11:31 am ET
Enzo Biochem to Report Fourth Quarter 2022 Financial Results and Business Update on Friday, October 14th
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter 2022 financial results on Friday, October 14, 2022, premarket. The announcement will be followed by a live audio...
Oct 06, 2022 08:00 am ET
Enzo Biochem, Inc. Opens Expanded Life Sciences Laboratory and Office Facilities in Farmingdale, New York
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the official launch of the Company’s new 100,000 square foot state-of-the-art laboratory and research facilities in...
Sep 26, 2022 08:00 am ET
Enzo Biochem, Inc. Launches AMPIVIEW™ Gene Expression Platform with First Products Targeting Detection of HPV and SARS-CoV-2
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the launch of the AMPIVIEW™ line, a breakthrough RNA gene expression platform powered by Enzo’s LoopRNA™ in situ hybridization...
Aug 11, 2022 08:00 am ET
Enzo Biochem to Launch Monkeypox Testing Services this Week
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that its full-service clinical laboratory will begin accepting specimens for monkeypox (MPX) testing this week. Mr. Hamid...
Aug 03, 2022 08:00 am ET
Enzo Biochem Appoints Matthew Kupferberg as General Counsel
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the addition of Matthew Kupferberg as the Company’s in-house General Counsel.   Mr. Hamid Erfanian, Chief Executive...
Jun 09, 2022 04:30 pm ET
Enzo Biochem Reports Third Quarter Fiscal 2022 Results and Provides Leadership and Corporate Updates Including Engagement of Jefferies as Financial Advisor
Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the third fiscal quarter ended April 30, 2022, and provided a business update on recent corporate and operational developments....
Jun 06, 2022 08:30 am ET
UPDATE -- Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close. The announcement will be followed by a live...
Jun 02, 2022 05:05 pm ET
Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2022 financial results on Thursday, June 9, 2022, after the market close. The announcement will be followed by a live...
Apr 19, 2022 08:00 am ET
Enzo Biochem Announces New York State Department of Health Approval of HPV Molecular Diagnostic Test
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced that it has received approval from the New York State Department of Health (DOH) for its AMPIPROBE® HPV test. The AMPIPROBE® HPV test...
Apr 12, 2022 08:30 am ET
Enzo Biochem Reports Results of its Annual Meeting of Shareholders
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced the approval of all proposals presented at its most recent Annual Meeting of Shareholders. “Approval of these proposals improves our...
Apr 06, 2022 04:57 pm ET
Enzo Biochem Adjourns Annual Meeting of Shareholders to Complete Vote on Proposal
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, held its Annual Shareholder Meeting (the “Annual Meeting”) on March 31, 2022 with 89% of the total 48.5 million shares voted. Out of four...
Apr 01, 2022 08:00 am ET
Enzo Biochem Adjourns Annual Meeting of Shareholders Until April 8, 2022
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced its 2021 Annual Meeting of Shareholders (“Annual Meeting”), with respect to Proposal 1, has been adjourned until April 8, 2022...
Mar 28, 2022 04:17 pm ET
Enzo Biochem Appoints David Bench and Kara Cannon to New Executive Management Positions
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced two key appointments to its new management structure. The Company announced Kara Cannon has been named Chief Operating Officer...
Mar 14, 2022 04:10 pm ET
Enzo Biochem Reports Second Quarter Fiscal 2022 Result and Provides Leadership and Corporate Updates
Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the second quarter ended January 31, 2022 and provided a business update on recent corporate and operational developments. “The...
Mar 10, 2022 08:37 am ET
Enzo Biochem to Present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum
Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum, Tuesday, March 22, 2022 at 3:00pm Eastern Time. The...
Mar 08, 2022 08:29 am ET
Enzo Biochem to Report Second Quarter 2022 Financial Results and Business Update on Monday, March 14th
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report second quarter 2022 financial results on Monday, March 14, 2022, after the market close. The announcement will be followed by a live...
Jan 03, 2022 04:10 pm ET
Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem’s Board of Directors
Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointments of Hamid Erfanian and Bradley Radoff to the Company’s Board of Directors (the “Board”), effective...
Dec 15, 2021 04:05 pm ET
Enzo Biochem Reports First Quarter 2022 Financial Results and Provides Business Update
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported financial results for the first quarter ended October 31, 2021 and provided a business update on recent corporate and operational developments. This...
Dec 02, 2021 04:05 pm ET
Enzo Biochem to Report First Quarter 2022 Financial Results and Business Update on Wednesday, December 15th
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter 2022 financial results on Wednesday, December 15, 2021, after the market close. The announcement will be followed by a...
Nov 09, 2021 10:18 am ET
ENZO BIOCHEM REPORTS INDUCEMENT AWARDS TO NEW CHIEF EXECUTIVE OFFICER
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that on November 8, 2021, it granted equity awards to Hamid Erfanian. Consistent with the disclosures contained in the Company’s...
Oct 25, 2021 08:00 am ET
Bradley L. Radoff Issues Letter to the Independent Directors of Enzo Biochem Regarding Their Unwillingness to Acknowledge or Address Unprecedented Shareholder Unrest
Bradley L. Radoff, who together with his affiliates holds approximately 7.5% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to the independent members of the Company’s Board of Directors (the “Board”):
Oct 21, 2021 08:38 am ET
Enzo Biochem Expands GoTestMeNow™ Online Portal to Provide Patients with Direct Access to Private Testing for Sexually Transmitted Infections
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company,  today announced the expansion of its GoTestMeNow™ online portal to enable individuals to directly access physician-authorized laboratory testing for sexually transmitted...
Oct 19, 2021 07:00 am ET
Bradley L. Radoff Issues Open Letter to Recently-Appointed Independent Directors of Enzo Biochem
Bradley L. Radoff, who together with his affiliates holds approximately 7.2% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to Dr. Mary Tagliaferri and Dr. Ian B. Walters, who joined the Company’s Board of Directors (the “Board”) in November 2020:
Oct 18, 2021 08:17 am ET
HAMID ERFANAIN NAMED CHIEF EXECUTIVE OFFICER OF ENZO BIOCHEM TO ACCELERATE EXPANSION AND COMMERCIALIZATION OF KEY DIAGNOSTIC PLATFORMS
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today the appointment of Hamid Erfanian as Chief Executive Officer. Following the succession plan announced in March and the...
Oct 12, 2021 07:00 am ET
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the fiscal year and fourth quarter ended July 31, 2021 and provided a business update on recent corporate and operational...
Sep 28, 2021 08:00 am ET
Enzo Biochem to Report Fourth Quarter and Full Year 2021 Financial Results and Business Update on Tuesday, October 12th
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter and fiscal year 2021 financial results on Tuesday, October 12, 2021, before the market open. The announcement will be...
Sep 02, 2021 04:05 pm ET
ENZO BIOCHEM TO PRESENT AT THE H.C. WAINWRIGHT 23RD ANNUAL GLOBAL INVESTMENT CONFERENCE
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually from September 13th - 15th. An...
Jul 20, 2021 08:00 am ET
ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR RAPID EXTRACTION METHOD ON PROPRIETARY TEST SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that it has received an expansion of its FDA Emergency Use Authorization (EUA) for the Company’s rapid extraction method on its...
Jun 15, 2021 12:00 pm ET
Enzo Biochem Announces Online Service with TrustAssure to Schedule Timely PCR Testing Required for International Travel
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, and CLX Health, developer of cloud-based solutions to manage the COVID-19 testing ecosystem through its TrustAssure™ Global Network, today...
Jun 09, 2021 04:05 pm ET
Enzo Biochem Reports Third Quarter Fiscal 2021 Results
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the third quarter ended April 30, 2021 and provided a business update on recent corporate and operational developments. Enzo...
Jun 01, 2021 04:05 pm ET
Enzo Biochem to Report Third Quarter 2021 Financial Results on Wednesday, June 9
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report third quarter 2021 financial results on Wednesday, June 9, 2021, after the market close. The announcement will be followed by a live...
Apr 21, 2021 08:00 am ET
Enzo’s Universal AMPICOLLECT™ Used on GENFLEX® Molecular Platform Cleared for Distribution by FDA Under Emergency Use Authorization
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Food and Drug Administration (“FDA”) has cleared its AMPICOLLECT™ Sample Collection kit (manufactured under GMP) for...
Mar 17, 2021 04:15 pm ET
ENZO BIOCHEM TO PRESENT AT THE KEYBANC CAPITAL MARKETS' LIFE SCIENCES & MEDTECH INVESTOR FORUM
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that management will present at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum, Tuesday March 23rd at 10:45am ET. The format will be...
Mar 15, 2021 04:05 pm ET
Enzo Biochem Reports Second Quarter Fiscal 2021 Results; Company Provides Leadership and Corporate Updates
Enzo Biochem, Inc (NYSE: ENZ), a leading biosciences and diagnostics company, today reported financial results for the second quarter ended January 31, 2021 and provided a business update on recent corporate and operational developments. “The...
Mar 04, 2021 08:00 am ET
Enzo Biochem to Participate in the H.C. Wainwright Global Life Sciences Conference
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Company will present at H.C. Wainwright Global Life Sciences Conference, which is being held virtually from March 9-10,...
Mar 02, 2021 08:00 am ET
Enzo Announces its GENFLEX™ Molecular Test Detects Current COVID-19 Variants
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced results of an analysis showing that tests processed on the Company’s proprietary GENFLEX™ molecular diagnostic platform are...
Mar 01, 2021 04:05 pm ET
Enzo Biochem to Report Second Quarter 2021 Financial Results on Monday, March 15
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, announced today that it will report second quarter 2021 financial results on Monday, March 15, 2021, after the market close. The announcement...
Feb 03, 2021 08:29 am ET
Enzo Announces Issuance of U.S. Patent for Polyclonal Antibodies Against Osteoporosis Drug Target Sclerostin
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,899,827 entitled “Antibodies Specific for Sulfation Sites of Sclerostin”. The...
Jan 20, 2021 08:13 am ET
ENZO BIOCHEM’S BOARD OF DIRECTORS FORMS NEW CORPORATE DEVELOPMENT AND PLANNING & SUCCESSION COMMITTEES
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced that the Enzo Board of Directors has formed two new committees to support strategy related to targeting and execution of new...
Jan 05, 2021 12:27 pm ET
Roumell Announces Preliminary Annual Meeting Results for Enzo Biochem, Inc.
CHEVY CHASE, Md., Jan. 5, 2021 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock (the "Common Stock") of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or "the Company"), today announced the preliminary results at the Company's annual meeting of shareholders held on January 4, 2021 (the "Annual Meeting") based on the tally by Roumell's proxy solicitor.
Jan 05, 2021 08:00 am ET
ENZO BIOCHEM TO PARTICIPATE IN THE LIFESCI PARTNERS 10TH ANNUAL HEALTHCARE CORPORATE ACCESS EVENT
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021 in concurrence...
Jan 04, 2021 07:00 am ET
ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR TESTING POOLED SAMPLES ON THREE PLATFORMS INCLUDING COMPANY’S GENFLEX™ PROPRIETARY SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has received an expansion of its Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA)...
Dec 31, 2020 12:46 pm ET
Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend That Shareholders Vote AGAINST Elazar Rabbani at Enzo's Upcoming Annual Meeting
CHEVY CHASE, Md., Dec. 31, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or "the Company"), today acknowledged that each of Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co., LLC ("Glass Lewis"), the world's leading proxy advisory firms, have recognized the need for change to the status quo in Enzo's boardroom by recommending against the re-election of Enzo Chairman and co-founder, Elazar Rabbani, Ph.D., to the board of directors (the "Board") at the
Dec 28, 2020 08:00 am ET
ENZO RESPONDS AFTER REVIEWING THE POSITION OF INSTITUTIONAL SHAREHOLDER SERVICES
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the position of Institutional Shareholder Services (“ISS”) regarding the Company's executive compensation...
Dec 24, 2020 01:06 pm ET
Roumell Asset Management Files Definitive Proxy Statement and Sends Letter to Enzo Biochem Shareholders
CHEVY CHASE, Md., Dec. 24, 2020 /PRNewswire/ -- Roumell Asset Management, LLC ("Roumell"), which owns 5.78% of the outstanding shares of common stock of Enzo Biochem, Inc.(NYSE: ENZ) ("Enzo" or "the Company"), filed definitive proxy materials yesterday with the Securities and Exchange Commission in connection with the Company's upcoming annual meeting of shareholders (the "Annual Meeting") currently scheduled to be held on January 4, 2021.  
Dec 15, 2020 08:00 am ET
Enzo Biochem Hosting Key Opinion Leader Call on GENFLEX™ Molecular System for COVID-19 and the Role of Testing in a Post-Vaccine Treatment Environment
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it will host a key opinion leader (KOL) webinar discussing the use of the GENFLEX™ Molecular System for COVID-19 testing and the role of testing in a...
Dec 09, 2020 04:01 pm ET
Enzo Biochem Reports First Quarter Fiscal 2021 Financial Results and Provides Business Update
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported financial results for the first quarter ended October 31, 2020 and provided a business update on recent corporate and operational developments. “During...
Dec 02, 2020 08:00 am ET
Enzo Biochem to Report First Quarter 2021 Financial Results on Wednesday, December 9
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter 2021 financial results on Wednesday, December 9, 2020, after the market close. The announcement will be followed by a...
Nov 25, 2020 08:00 am ET
ENZO BIOCHEM ANNOUNCES APPOINTMENT OF IAN B. WALTERS, MD, TO ITS BOARD OF DIRECTORS
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that Ian B. Walters, MD, has been appointed to the Company’s Board of Directors effective immediately.     Dr. Walters is an...
Nov 18, 2020 01:00 pm ET
Harbert Discovery Fund Issues Letter to Enzo Biochem Board of Directors
Elazar Rabbani, Dov Perlysky, Rebecca Fischer, We are writing to demand Elazar Rabbani immediately resign as CEO and from the Board of Directors (the “Board”) of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”). Harbert Discovery Fund,...
Nov 18, 2020 08:05 am ET
ENZO BIOCHEM ANNOUNCES APPOINTMENT OF MARY TAGLIAFERRI, MD, TO ITS BOARD OF DIRECTORS
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “the Company”), a leading biosciences and diagnostics company, announced today that Mary Tagliaferri, MD, has been appointed to the company’s Board of Directors effective immediately.    “In 2020, Enzo...
Nov 17, 2020 08:00 am ET
ENZO PROVIDES CORPORATE BUSINESS UPDATE
Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that the company estimates revenue to meet or exceed $27 million, representing sequential growth of at least 40%, for the...
Nov 05, 2020 08:00 am ET
ENZO LAUNCHES PORTABLE MICROPLATE READER FOR USE WITH ITS ELISA AND ASSAY KITS TO SIMPLIFY LABORATORY WORKFLOW
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today the commercial launch of a small portable microplate reader for use with the company’s immunoassays and, ultimately, molecular diagnostics, providing new...
Oct 27, 2020 08:00 am ET
ENZO BIOCHEM LAUNCHES GOTESTMENOW™ ONLINE PLATFORM FOR CONSUMERS TO DIRECTLY ORDER COVID-19 LABORATORY TESTS
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it has launched GoTestMeNow™, a new online platform that enables consumers to directly order physician-authorized laboratory testing....
Oct 13, 2020 04:01 pm ET
Enzo Biochem Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported financial results for the fourth quarter and full year ended July 31, 2020 and provided a business update on recent corporate and operational...
Oct 06, 2020 03:42 pm ET
Enzo Biochem to Report Fourth Quarter and Fiscal Year 2020 Financial Results on Tuesday, October 13
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report fourth quarter and fiscal year 2020 financial results on Tuesday, October 13, 2020, after the market close. The announcement will be...
Sep 08, 2020 08:00 am ET
ENZO BIOCHEM DOUBLES CAPACITY IN RESPONSE TO INCREASING DEMAND FOR COVID-19 TESTING
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it has expanded reagent and supply manufacturing as well as doubled its capacity for molecular laboratory testing services at its facilities in...
Jul 21, 2020 08:30 am ET
ENZO BIOCHEM TO PROVIDE ACCESS TO COVID-19 TESTING AT MORE THAN 50 NY PHARMACIES IN COLLABORATION WITH CPESN NY
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostic company, and Community Pharmacy Enhanced Services Network (CPESN® NY), the New York division of the clinically integrated, nationwide organization of pharmacy networks, announced...
Jul 13, 2020 08:30 am ET
Enzo Biochem Receives Emergency Use Authorization for Proprietary Test System for Detection of Coronavirus SARS-CoV-2
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it has formally received Emergency Use Authorization (EUA) for its proprietary product for the detection of Coronavirus SARS-CoV-2. The...
Jun 30, 2020 01:15 pm ET
Enzo Biochem to Provide COVID-19 Testing to Farmingdale State College Staff and Students as They Return to Campus
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostic company, and Farmingdale State College today announced they are partnering to provide molecular and antibody testing for COVID-19 to the campus community as the college reopens...
Jun 23, 2020 08:30 am ET
Enzo Announces Issuance of U.S. Patent for Methods of Treating Liver Cancer Using Proprietary Compound SK1-I
Enzo Biochem, Inc. (NYSE: ENZ), a leading biosciences and diagnostics company, today announced it has received a patent for the treatment of liver cancer, U.S. Patent No. 10,675,255 entitled Sphingosine Pathway Modulating Compounds for the...
Jun 08, 2020 04:05 pm ET
Enzo Biochem Reports Third Quarter 2020 Financial Results
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported results for the third quarter ended April 30, 2020. Elazar Rabbani, PhD., Chairman and Chief Executive Officer, said: “The COVID-19 pandemic has brought...
Jun 03, 2020 04:05 pm ET
Enzo Biochem to Announce Third Quarter 2020 Financial Results on Monday June 8, 2020
Enzo Biochem, Inc.  (NYSE: ENZ) a leading biosciences and diagnostics company, today announced that it will release its third quarter 2020 financial results after the market closes on Monday June 8, 2020. The company’s President Barry Weiner and...
May 20, 2020 08:00 am ET
Enzo Biochem Launches Proprietary Test for Detection of Coronavirus SARS-CoV-2 IgG Antibody Under FDA’s Emergency Use Authorization
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today announced that it is currently offering a SARS-CoV-2 IgG ELISA assay kit for serological detection of IgG antibodies against the novel coronavirus under the FDA’s...
May 12, 2020 08:00 am ET
Enzo Announces Issuance of U.S. Patent for Methods of Producing Monoclonal Antibodies Against Osteoporosis Drug Target Sclerostin
Enzo Biochem, Inc.  (NYSE: ENZ) a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,626,170 entitled Sulfonated Sclerostin, Antibodies, Epitopes and Methods for Identification and Use Therefor....
Apr 29, 2020 08:00 am ET
Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19
Enzo Biochem, Inc.  (NYSE: ENZ), a leading biosciences and diagnostics company, today announced the recent issuance of U.S. Patent No. 10,624,863 entitled Sphingosine Kinase Type 1 Inhibitors and Uses Thereof.  The patent is directed to methods for...
Apr 23, 2020 08:00 am ET
Enzo Biochem Launches Proprietary COVID-19 Diagnostic Test Under FDA’s Emergency Use Authorization
Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostic company, today announced its Comprehensive COVID-19 Program incorporating its molecular diagnostic virus screening products, detection for immunity through IgG/IgM serological ELISA products, detection of inflammation on Enzo’s ELISA platform, and a promising proprietary drug candidate (SK1-I). Enzo is utilizing its technological and research and development capabilities, manufacturing infrastructure strength and clinical diagnostic capabilities to provide products that address gaps in performance, cost, supply obtainability a
Mar 24, 2020 07:30 am ET
Enzo Biochem’s Clinical Labs Subsidiary Launches Drive-Through Facility to Provide COVID-19 Testing on Long Island
Enzo Biochem, Inc. (NYSE:ENZ), a leading biotechnology and diagnostic company, today announced its wholly owned subsidiary, Enzo Clinical Labs, Inc., has expanded its screening services for COVID-19. Following the company’s March 6, 2020 announcement regarding the initiation of accepting specimens for novel Coronavirus (COVID-19) testing, Enzo is now directly collecting specimens at a drive-through facility by appointment in Enzo’s laboratory complex in Farmingdale, New York. This facility has been set up with support from local and state officials.
Mar 06, 2020 08:00 am ET
Enzo Biochem’s Full Service Clinical Laboratory to Launch Coronavirus (COVID-19) Testing Services Next Week
Enzo Biochem, Inc. (NYSE:ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc., will begin accepting specimens for novel Coronavirus (COVID-19) testing next week. COVID-19 is a contagious virus that is believed to spread by person-to-person transmission and may have serious health consequences. The virus has infected more than 93,000 people globally including recent detections in the United States. Enzo has many years of experience processing specimens for the detection of viral pathogens. The test used by Enzo is a molecular test that determines the presence of viral
Mar 05, 2020 04:05 pm ET
Enzo Biochem Reports Fiscal Second Quarter Results
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics company focusing on delivering and applying advanced technology to produce affordable, reliable diagnostic products and services, today reported results for the fiscal second quarter ended January 31, 2020.
Mar 03, 2020 10:00 am ET
Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2020 Results Friday, March 6, 2020 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2020 second quarter results on Friday, March 6, 2020, at 8:30 AM E.T.
Feb 25, 2020 10:27 am ET
Shareholders Support the Election of Both HDF Nominees to Enzo Board of Directors
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that, based on a preliminary vote count provided by its proxy solicitor, Enzo shareholders voted to elect HDF nominees, Fabian Blank and Peter Clemens, and Company nominee Rebecca Fischer, to the Board of Directors (the “Board”) at the Company’s 2019 Annual Meeting of Shareholders (the “Annual Meeting”) today.
Feb 25, 2020 09:59 am ET
Enzo Biochem Announces Preliminary Results of Voting at Annual Shareholder Meeting
Enzo Biochem (NYSE:ENZ) announced preliminary results of voting at the 2019 Annual Shareholder meeting held today.
Feb 19, 2020 05:16 pm ET
ISS Recommends Shareholders Vote AGAINST Enzo Proposal to Increase Size of Board
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that a leading proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that shareholders vote on the BLUE proxy card AGAINST Enzo’s proposal to amend its bylaws in order to increase the size of the Board and re-nominate Barry Weiner. Enzo’s delayed 2019 Annual Meeting of Shareholders (the “Annual Meeting”) is scheduled for Febru
Feb 19, 2020 08:30 am ET
Enzo Biochem Reports Publication of Study Detailing Promising Activity of Drug Candidate SK1‑I in a Model of Lupus
Enzo Biochem, Inc. (NYSE:ENZ) today announced the publication of a study in The FASEB Journal by academic researchers that shows drug candidate “SK1‑I,” the company’s proprietary Sphingosine Kinase 1 inhibitor, markedly reduced Lupus-associated parameters in a recognized, chemically-induced animal model of Systemic Lupus Erythematosus, commonly known as “Lupus.” This treatment resulted in reductions in interferon (IFN) signature, pDC activation and glomerulonephritis, the inflammation of the filtration units of the kidney. Significantly, SK1-I was not only effective when administered simultane
Feb 11, 2020 08:30 am ET
Enzo Biochem Announces Significant Milestone with Approval of Proprietary GenFlex Platform
Enzo Biochem, Inc. (NYSE: ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc. has received New York State approval for its CT/NG/TV tests using liquid-based cytology sample collection on its proprietary GenFlex platform. GenFlex is a commercially available sample-to-result molecular diagnostic platform that includes sample collection, sample processing, amplification and detection. The GenFlex open system delivers high-throughput, high capacity, workflow efficiency and flexibility at a much greater level of affordability than existing systems.
Feb 07, 2020 08:00 am ET
Enzo Disappointed in Harbert’s Lawsuit Aimed at Disenfranchising Shareholders
Enzo Biochem, Inc. (NYSE:ENZ) (the “Company”) today disclosed that Harbert Discovery Fund, LP (“Harbert”) filed a lawsuit against the Company and the members of its board of directors (“Board”) in the U.S. District Court for the Southern District of New York.
Feb 06, 2020 03:07 pm ET
Harbert Discovery Fund Files Lawsuit Seeking to Hold Enzo Board Accountable for Acts of Entrenchment and Illegal Maneuvers
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that it has filed a complaint in the U.S. District Court for the Southern District of New York asserting direct claims against Enzo and asserting both direct and derivative claims against members of its Board of Directors (the “Board”) (Case 1:20-cv-01021). The complaint alleges that Enzo has engaged in brazen acts of entrenchment and misuse of the corporate
Jan 30, 2020 08:13 am ET
Enzo Comments on Harbert’s Reaction to Providing Enzo Shareholders Additional Choices
Enzo Biochem, Inc. (NYSE:ENZ) today commented on Harbert’s press release in reaction to Enzo’s announcement that it is providing its shareholders with additional choices:
Jan 29, 2020 10:51 am ET
Harbert Discovery Fund Comments on Enzo Biochem’s Entrenchment Maneuvers
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today issued the following statement commenting on Enzo’s January 28, 2020 press release announcing the postponement of its 2019 Annual Meeting of Shareholders (the “Annual Meeting”) to February 25, 2020 and proposing the potential expansion of its Board of Directors (the “Board”) to seven seats from the current five.
Jan 28, 2020 05:45 pm ET
Enzo Biochem Proposes to Increase Size of Board and Will Appoint Additional Highly Qualified, Diverse Independent Director in Near Future
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable and fully-automated platforms and related products and services that enable its customers to meet their clinical needs, today announced that Enzo’s board of directors (“Board”) has made a series of changes to the agenda for the upcoming Annual Meeting of Shareholders of the Company (“Annual Meeting”).
Jan 27, 2020 06:45 am ET
Harbert Discovery Fund Sends Letter to Fellow Enzo Biochem Shareholders
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today sent a letter to shareholders in connection with its efforts to elect two highly-qualified, fresh voices – Fabian Blank and Peter Clemens – to the Company’s Board of Directors (the “Board”) at its 2019 Annual Meeting of Shareholders (the “Annual Meeting”), which will be held on January 31, 2020.
Jan 21, 2020 02:36 pm ET
All Three Proxy Advisory Firms Recommend Shareholders Vote FOR Change to the Board of Enzo Biochem on the Blue Card
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that Egan-Jones Proxy Services (“Egan-Jones”) has recommended shareholders vote for both HDF nominees on the Blue proxy card. All three leading proxy advisors – Egan-Jones, Glass, Lewis and Co. (“Glass Lewis”) and Institutional Shareholder Services Inc. (“ISS”) – have now supported HDF’s case for change at Enzo.
Jan 17, 2020 03:02 pm ET
Enzo Biochem Comments on ISS Report
“While we strongly disagree with the recommendation of ISS to support one of the activist hedge fund’s nominees at the Annual Shareholder Meeting, we are gratified that ISS acknowledges the operational and governance progress across the Company. ISS highlights the dissident’s puzzling unwillingness to engage in constructive discussions with the Board, recognizes the significant refresh of Enzo’s Board over the last four years and highlights the meaningful improvements in a number of corporate governance areas. ISS also validates our contention several times in the report that the dissident dem
Jan 17, 2020 11:56 am ET
ISS Recommends Shareholders Vote FOR the Election of Harbert Discovery Fund Nominee to Enzo Biochem Board
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that a leading proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that shareholders vote on the BLUE proxy card in support of HDF’s nominee, Fabian Blank.
Jan 16, 2020 01:03 pm ET
Glass Lewis Recommends Shareholders Vote For the Election of Both Harbert Discovery Fund Nominees to Enzo Biochem’s Board
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today announced that a leading proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has recommended that shareholders vote on the BLUE proxy card in support of HDF’s two highly-qualified independent nominees, Fabian Blank and Peter Clemens.
Jan 13, 2020 08:00 am ET
Enzo Biochem Responds to Series of Misleading and Inaccurate Statements from Activist Hedge Fund Harbert
The Board of Directors of Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable and fully-automated platforms and related products and services that enable its customers to meet their clinical needs, today responded to a series of misleading and inaccurate statements in an investor presentation and press release filed by activist investor Harbert Discovery Fund (“Harbert”) regarding the Company’s significant accomplishments. The Board believes that Harbert’s campaig
Jan 08, 2020 09:00 am ET
Harbert Discovery Fund Releases Detailed Investor Presentation Highlighting Case for Change at Enzo Biochem
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owner of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), today released a detailed investor presentation on Enzo. The presentation outlines the Company’s history of value destruction, persistent underperformance, and corporate governance issues and details HDF’s Nominees’ strategic plan to realize value at Enzo.
Dec 31, 2019 10:48 am ET
Enzo Biochem Appoints Rebecca J. Fischer to Board of Directors
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today announced it has appointed industry healthcare veteran and leader Rebecca J. Fischer to its Board of Directors. Her appointment as a new independent director is effective immediately and follows a search process conducted as part of Enzo’s ongoing focus on Board composition, refreshment and diversity. As part of our evaluation, th
Dec 30, 2019 09:00 am ET
Harbert Discovery Fund Sends Letter to Fellow Enzo Biochem Shareholders
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owner of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), sent a detailed letter to shareholders today highlighting HDF’s case for change at Enzo, including the opportunity for shareholders to elect two highly-qualified, fresh voices – Fabian Blank and Peter Clemens – to the Company’s Board of Directors (the “Board”) at its 2019 Annual Meeting of Shareholders, which will be held on January 31, 2020.
Dec 10, 2019 04:15 pm ET
Enzo Biochem Reports Fiscal First Quarter Results
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today reported results for the fiscal first quarter ended October 31, 2019.
Dec 05, 2019 04:15 pm ET
Enzo Biochem Issues Open Letter to Shareholders
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today issued an open letter to shareholders. Full text below:
Dec 05, 2019 12:00 pm ET
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2020 Results Tuesday, December 10, 2019 At 4:30 PM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2020 first quarter results on Tuesday, December 10, 2019, at 4:30 PM E.T.
Oct 15, 2019 04:15 pm ET
Enzo Biochem Reports Fiscal Fourth Quarter and Full Year Financial Results
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics, clinical lab, and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today reported results for the fiscal fourth quarter and year ended July 31, 2019.
Oct 11, 2019 09:00 am ET
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal Year 2019 Results Tuesday, October 15, 2019 at 4:30 PM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2019 fourth quarter and fiscal year 2019 results on Tuesday, October 15, 2019, at 4:30 PM E.T.
Sep 24, 2019 09:00 am ET
New York State Health Department Approves Hepatitis B Virus Quantitative Clinical Assay
Enzo Biochem, Inc. (NYSE: ENZ) today announced that its wholly owned subsidiary, Enzo Clinical Labs, Inc. has received New York State approval for its AmpiProbe® HBV viral load monitoring assay for Hepatitis B virus (HBV) based on the Enzo assay’s performance versus an FDA-approved comparator product. This is a significant step forward for the Company as the approval of this HBV assay further extends Enzo’s portfolio in the viral load monitoring market where the company has already received New York State approval for a viral load monitoring assay for Hepatitis C virus (HCV) and is currently d
Sep 17, 2019 09:00 am ET
Harbert Discovery Fund Nominates Two Highly-Qualified Independent Candidates to Enzo Biochem Board
Harbert Discovery Fund, LP and Harbert Discovery Co-Investment Fund I, LP (collectively “HDF”), the beneficial owner of more than 11.8% of the outstanding shares of Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), announced today in a detailed letter to shareholders that it is nominating two director candidates for election to the Company’s Board of Directors (the “Board”) at its 2019 Annual Meeting of Shareholders.
Aug 05, 2019 09:00 am ET
Enzo Biochem, Inc. Announces Issuance of United States Patent for Advanced Nucleic Acid Hybridization Probe Technology for Clinical and Research Applications
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today announced the issuance of U.S. Patent No. 10,323,272 entitled Nucleic Acid Probes for In Situ Hybridization. The patent is related to a new probe technology developed by Enzo and transformative methods of testing using the probes, which allow for significantly more cost effective, simple and scalable processes across the multi-billion dollar diagnostic testing, drug development and academic research marketplace.
Jul 11, 2019 09:00 am ET
Enzo Biochem Announces Key Transformative Initiatives to Propel and Accelerate Growth In its Lab Business
Enzo Biochem, Inc. (NYSE: ENZ) today announced several key transformative initiatives in its labs business unit designed to propel and accelerate growth. The initiatives are part of a company-wide commitment to expand its market opportunity in diagnostic testing, capitalizing on Enzo’s history of innovation, differentiated business strategy and emerging market dynamics.
Jun 10, 2019 04:17 pm ET
Enzo Biochem Reports Fiscal Third Quarter and Nine Months Operating Results
Enzo Biochem, Inc. (NYSE:ENZ), an integrated life sciences company focused on commercializing innovative diagnostic and therapeutics products, today reported results for the fiscal quarter and nine months ended April 30, 2019. The Company updated the market on the progress of its short-term growth and profitability initiatives designed to unlock value.
Jun 05, 2019 09:00 am ET
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2019 Results Tuesday, June 11, 2019 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2019 third quarter results Tuesday, June 11, 2019, at 8:30 AM E.T.
May 10, 2019 10:48 am ET
Enzo Biochem Inc. Announces Issuance of United States Patent for Treatment of Liver Cancer Using Ozanimod
Enzo Biochem, Inc. (NYSE:ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine Pathway Modulating Compounds for the Treatment of Cancers” that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod.
Mar 11, 2019 04:10 pm ET
Enzo Biochem Reports Second Fiscal Quarter and First Half 2019 Results and Reports Progress on Its Investments and Strategic Goals
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.
Mar 05, 2019 04:05 pm ET
Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2019 Results Tuesday, March 12, 2019 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2019 second quarter results Tuesday, March 12, 2019, at 8:30 AM E.T.
Jan 29, 2019 07:35 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within The Hain Celestial Group, Allegheny Technologies, NVR, Greif, CorMedix, and Enzo Biochem — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Hain Celestial Group, Inc. (NASDAQ:HAIN), Allegheny Technologies...
Dec 10, 2018 04:15 pm ET
Enzo Biochem Reports Fiscal 2019 First Quarter Results
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today reported operating results for the first fiscal quarter ended October 31, 2018, in addition to providing an update on the company’s development of lower cost products, platforms and services for the diagnostics and therapeutics markets.
Dec 06, 2018 09:00 am ET
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2019 Results Tuesday, December 11, 2018 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostic and therapeutics company, will hold a conference call to discuss fiscal 2019 first quarter results Tuesday, December 11, 2018, at 8:30 AM E.T.
Dec 03, 2018 09:00 am ET
Enzo Biochem Reports Publication of Study on Therapeutic Candidate SK1-I Detailing Promising Results in a Model of Treatment-Resistant Breast Cancer
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today reported the publication of a study in the Journal of Lipid Research by researchers at a collaborating institution that shows SK1-I, the company’s proprietary Sphingosine Kinase 1 inhibitor drug candidate, was effective in reversing resistance to the breast cancer drug tamoxifen in a tamoxifen-resistant human breast cancer cell line. As pointed out in the publication, endocrine therapy, such as tamoxifen, is a first line treatment for estrogen recepto
Oct 29, 2018 08:25 am ET
Market Trends Toward New Normal in Polaris Industries, NIKE, Charles River Laboratories International, Actuant, Caesarstone, and Enzo Biochem — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Polaris Industries Inc. (NYSE:PII), NIKE, Inc. (NYSE:NKE), Charles...
Oct 15, 2018 04:05 pm ET
Enzo Biochem Reports Fourth Quarter and Fiscal 2018 Results
Enzo Biochem Inc. (NYSE:ENZ), an integrated diagnostic and therapeutics company, today reported results for the fourth quarter and fiscal year ended July 31, 2018, in addition to announcing New York State department of Health’s approval of additional assays for new women’s health infectious disease panel continuing to drive focus in development of lower cost products, platforms and services for the clinical laboratory market.
Oct 11, 2018 12:49 pm ET
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter and Fiscal 2018 Results Tuesday, October 16, 2018 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 fourth quarter and year end results Tuesday, October 16, 2018, at 8:30 AM E.T.
Aug 27, 2018 08:30 am ET
Enzo Biochem to Acquire New Facility for Manufacturing and Distribution to Advance Its Diagnostic and Therapeutic Growth Strategy
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostic and therapeutics company, announced today that, as part of implementing its growth strategy, it has entered into an agreement to purchase a commercial facility with nearly 36,000 square feet in Farmingdale, NY. The building is adjacent to the Company’s current Long Island campus and enhances the infrastructure needed to produce and distribute Enzo’s expanding low cost, diagnostic platform products and related services. The Company’s platform development includes automation-compatible reagen
Aug 02, 2018 08:15 am ET
Market Trends Toward New Normal in Sandy Spring, Tupperware Brands, Dolby Laboratories, AeroVironment, Barnes Group, and Enzo Biochem — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sandy Spring Bancorp, Inc. (NASDAQ:SASR), Tupperware Brands Corporation...
Jul 18, 2018 09:00 am ET
Enzo Biochem Reports Validation of Three High Quality, Low Cost Biomarkers for Detecting Cancers and Their Progression, Especially in Women’s Health Area
Enzo Biochem Inc. (NYSE:ENZ) today announced the validation of three clinically relevant, cost-efficient biomarker detection tests for charting the progression of various cancers, especially in the field of women’s health. These cost effective, high quality primary antibodies function with our full open system workflow and complement Enzo’s strategy of introducing lower cost testing solutions for the clinical laboratory market.
Jun 11, 2018 04:10 pm ET
Enzo Biochem Reports Third Quarter Results
Enzo Biochem Inc. (NYSE:ENZ), an integrated diagnostic company, today reported results for the third fiscal quarter and nine months ended April 30, 2018, in addition to noting significant progression of its strategic plan aimed at providing cost-effective, high performing and easily adaptable products and services to hospital and independent laboratories.
Jun 06, 2018 10:00 am ET
Enzo Biochem Schedules Teleconference to Discuss Third Quarter 2018 Results Tuesday, June 12, 2018 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 third quarter results Tuesday, June 12, 2018, at 8:30 AM E.T.
Apr 24, 2018 10:00 am ET
Patent Trial and Appeal Board Denies Hologic Challenge to Enzo Biochem Patent Involved in Delaware Infringement Case
Enzo Biochem, Inc. (NYSE:ENZ) and its subsidiary Enzo Life Sciences, Inc. today announced that the Patent Trial and Appeal Board has denied a petition filed by Hologic, Inc. (NASDAQ:HOLX) for inter partes review, a procedure for challenging the validity of patent claims, against U.S. Patent 6,221,581. Enzo Life Sciences, Inc. is asserting U.S. Patent 6,221,581 in patent infringement litigation against Hologic, Inc., Grifols Diagnostic Solutions, Inc., and Grifols S.A. in the U.S. District Court for the District of Delaware.
Apr 24, 2018 08:25 am ET
Report: Exploring Fundamental Drivers Behind Enzo Biochem, The Hackett Group, Rexford Industrial Realty, Green Plains, United Community Banks, and Encore Capital Group — New Horizons, Emerging Trends,
NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Enzo Biochem, Inc. (NYSE:ENZ), The Hackett...
Mar 12, 2018 04:05 pm ET
Enzo Biochem Reports Second Quarter and First Half Results
Enzo Biochem Inc. (NYSE:ENZ) today announced results for the fiscal quarter and six months ended January 31, 2018.
Mar 08, 2018 04:10 pm ET
Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2018 Results Tuesday, March 13, 2018 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 second quarter results Tuesday, March 13, 2018, at 8:30 AM E.T.
Feb 26, 2018 07:30 am ET
Exploring Fundamental Drivers Behind Enzo Biochem, RPX, The Hackett Group, 2U, AK Steel Holding, and Och-Ziff Capital Management Group — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Enzo Biochem, Inc. (NYSE:ENZ), RPX Corporation...
Jan 22, 2018 09:00 am ET
Enzo Biochem Announces New Validated Cost-Effective Cervical Cancer Biomarker Detection Test
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics company, announced today validation of a cervical cancer biomarker detection test that provides a highly robust and cost-efficient solution for anatomical pathology.
Dec 19, 2017 07:50 am ET
Report: Exploring Fundamental Drivers Behind Allstate, Ashford Hospitality Prime, S&P Global, Enzo Biochem, Seres Therapeutics, and HFF — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Allstate Corporation (NYSE:ALL), Ashford Hospitality Prime,...
Dec 08, 2017 07:00 am ET
Enzo Biochem, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / December 8, 2017 / Enzo Biochem, Inc. (NYSE: ENZ) will be discussing their earnings results in their Q1 Earnings Call to be held on December 8, 2017 at 8:30 AM Eastern Time.
Dec 07, 2017 04:10 pm ET
Enzo Biochem Reports Improved First Quarter Results
Enzo Biochem Inc. (NYSE:ENZ) today reported improved operating results for the first fiscal quarter ended October 31, 2017, including year over year double digit revenue growth at Enzo Clinical Labs.
Dec 05, 2017 08:00 am ET
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2018 Results Friday, December 8, 2017 at 8:30 AM E.T.
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2018 first quarter results Friday, December 8, 2017, at 8:30 AM E.T.
Oct 23, 2017 08:30 am ET
Enzo Biochem Announces NYS Department of Health’s Approval of a New Women’s Health Infectious Disease Panel
Enzo Biochem Inc. (NYSE:ENZ) today announced it has received approval of another women’s health infectious disease diagnostic panel, which when combined with the Company’s previously approved panels, makes for one of the most comprehensive, efficient and affordable diagnostic products and services on the market today. A variety of infections, including sexually transmitted ones, are detected from a single vaginal swab collection via the Company’s proprietary, versatile and cost-effective AMPIPROBE® platform. The announcement results f

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.